Banco Santander S.A. Has $7.96 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Banco Santander S.A. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.7% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 7,571 shares of the biopharmaceutical company’s stock after acquiring an additional 126 shares during the period. Banco Santander S.A.’s holdings in Regeneron Pharmaceuticals were worth $7,957,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Atria Wealth Solutions Inc. grew its position in Regeneron Pharmaceuticals by 12.4% in the 4th quarter. Atria Wealth Solutions Inc. now owns 1,971 shares of the biopharmaceutical company’s stock valued at $1,731,000 after purchasing an additional 218 shares during the period. Gilbert & Cook Inc. increased its position in shares of Regeneron Pharmaceuticals by 8.3% during the fourth quarter. Gilbert & Cook Inc. now owns 1,907 shares of the biopharmaceutical company’s stock worth $1,675,000 after acquiring an additional 146 shares in the last quarter. Choreo LLC bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $920,000. Intrust Bank NA raised its holdings in shares of Regeneron Pharmaceuticals by 3.3% in the 4th quarter. Intrust Bank NA now owns 1,673 shares of the biopharmaceutical company’s stock worth $1,469,000 after acquiring an additional 53 shares during the last quarter. Finally, Adell Harriman & Carpenter Inc. lifted its position in Regeneron Pharmaceuticals by 33.1% in the 4th quarter. Adell Harriman & Carpenter Inc. now owns 507 shares of the biopharmaceutical company’s stock valued at $445,000 after acquiring an additional 126 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded down $20.36 during trading hours on Thursday, hitting $1,178.93. 538,607 shares of the company’s stock were exchanged, compared to its average volume of 467,635. The company has a market capitalization of $129.90 billion, a PE ratio of 34.83, a PEG ratio of 3.12 and a beta of 0.13. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 12-month low of $769.19 and a 12-month high of $1,211.20. The business’s 50 day simple moving average is $1,097.60 and its 200-day simple moving average is $1,009.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same period in the previous year, the firm posted $8.79 earnings per share. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Bonnie L. Bassler sold 827 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The stock was sold at an average price of $1,011.00, for a total transaction of $836,097.00. Following the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at $1,397,202. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The disclosure for this sale can be found here. Insiders have sold a total of 22,239 shares of company stock worth $23,933,880 in the last ninety days. 7.48% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have commented on REGN. Barclays boosted their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Truist Financial reiterated a “buy” rating and set a $1,200.00 price target (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 2nd. JPMorgan Chase & Co. increased their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Wells Fargo & Company raised their price target on shares of Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Finally, Evercore ISI assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price objective for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $1,108.45.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.